Immune-Onc Therapeutics

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies that target myeloid cells, a critical component of the immune system. Their approach leverages a deep understanding of myeloid cell biology and immune inhibitory receptors, aiming to create first-in-class biotherapeutics that can reverse immune suppression in the tumor microenvironment. They are currently developing a portfolio of promising therapeutics across various stages of development, including IO-108, an antagonist antibody targeting LILRB2 for solid tumors, and IO-202, a first-in-class antagonist antibody targeting LILRB4 for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors.

Immune-Onc has established collaborations with leading biopharmaceutical companies like BeiGene, Regeneron, and Roche to support its global product development plans. They have also received research grants from the National Cancer Institute (NCI) and the California Institute for Regenerative Medicine (CIRM), demonstrating their commitment to advancing cutting-edge research. With their innovative approach and strong industry partnerships, Immune-Onc is well-positioned to develop transformative therapies for patients with challenging cancers and other immune-related diseases.

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies that target myeloid cells, specifically the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB). Their mission is to translate scientific insights in myeloid cell biology and immune inhibitory receptors into first-in-class biotherapeutics that reverse immune suppression in the tumor microenvironment, ultimately leading to improved treatment options for patients with various cancers, autoimmune, and inflammatory diseases.

Immune-Onc Therapeutics fosters a culture of innovation and collaboration, centered around a deep commitment to improving the lives of patients battling cancer and autoimmune diseases. They value a diverse team of scientists, translational medicine experts, and clinical development professionals who are driven by challenge and dedicated to making a meaningful impact. The company's culture emphasizes caring for science, patients, and each other, creating a supportive environment where everyone can contribute to achieving their shared aspirations.

Immune-Onc Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace that values the unique perspectives and contributions of all individuals. The company actively seeks to create a culture where everyone feels respected, valued, and empowered to succeed. They strive to build a diverse team with deep expertise in drug development and proven track records of success at leading biopharmaceutical companies, ensuring fair and equitable treatment for all employees. Immune-Onc believes that a diverse workforce is essential for innovation and progress, and they are actively working to create an environment where everyone feels welcome, respected, and empowered to reach their full potential.